Success Metrics

Clinical Success Rate
82.2%

Based on 37 completed trials

Completion Rate
82%(37/45)
Active Trials
6(10%)
Results Posted
65%(24 trials)
Terminated
8(13%)

Phase Distribution

Ph phase_4
19
30%
Ph phase_1
7
11%
Ph not_applicable
6
10%
Ph phase_2
14
22%
Ph early_phase_1
2
3%
Ph phase_3
10
16%

Phase Distribution

9

Early Stage

14

Mid Stage

29

Late Stage

Phase Distribution58 total trials
Early Phase 1First-in-human
2(3.4%)
Phase 1Safety & dosage
7(12.1%)
Phase 2Efficacy & side effects
14(24.1%)
Phase 3Large-scale testing
10(17.2%)
Phase 4Post-market surveillance
19(32.8%)
N/ANon-phased studies
6(10.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.2%

37 of 52 finished

Non-Completion Rate

28.8%

15 ended early

Currently Active

6

trials recruiting

Total Trials

63

all time

Status Distribution
Active(6)
Completed(37)
Terminated(15)
Other(5)

Detailed Status

Completed37
Terminated8
Withdrawn7
Recruiting5
unknown4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
63
Active
6
Success Rate
82.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.4%)
Phase 17 (12.1%)
Phase 214 (24.1%)
Phase 310 (17.2%)
Phase 419 (32.8%)
N/A6 (10.3%)

Trials by Status

active_not_recruiting12%
withdrawn711%
terminated813%
suspended12%
completed3759%
recruiting58%
unknown46%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT03616236Phase 3

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Suspended
NCT04771689Phase 4

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

Withdrawn
NCT04091009Phase 4

Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms

Withdrawn
NCT05450718Phase 4

Low-dose Buprenorphine Initiation for Opioid Use Disorder

Recruiting
NCT05944952Phase 4

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Active Not Recruiting
NCT04893525Phase 2

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Recruiting
NCT05011266Phase 2

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

Recruiting
NCT04447287Phase 1

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Completed
NCT04818086Phase 1

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Completed
NCT05062577Phase 2

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Withdrawn
NCT03908437Phase 4

Rapid Initiation of Drug Treatment Engagement

Completed
NCT05644587Phase 4

Novel Induction to Buprenorphine/Naloxone

Terminated
NCT04480554Phase 2

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

Recruiting
NCT04234191Phase 2

Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Recruiting
NCT04794790Early Phase 1

Buprenorphine Induction for Fentanyl Dependent Opioid Users

Withdrawn
NCT03976258

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

Completed
NCT01843751Phase 3

Dane County Drug Court Study for Addicted Offenders

Completed
NCT03026790Phase 2

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

Completed
NCT05307458

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

Unknown
NCT00684073Phase 4

Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
63